TickerHumNASDAQ · Healthcare · Drug Manufacturers—General
Gilead Sciences, Inc. (GILD)
As of Nov 11, 1:50 PM ET, Gilead Sciences (GILD) last traded at $169.77, down 0.64% on the day. Its TickerHum research score is 45/100 (average). It reported revenue of $30.99B for the twelve months ending 2026-09-30, up 6.5% year over year, with a -7.6% operating margin.
Ratings
- Valuation: 55/100 — Strongest input: free-cash-flow yield 6.5 %. Weakest: price / earnings (ttm) Negative earnings.
- Growth: 21/100 — Strongest input: revenue growth (ttm, yoy) +6.5 %. Weakest: diluted eps growth (ttm, yoy) -148.5 %.
- Profitability: 2/100 — Strongest input: operating margin -7.6 %. Weakest: return on equity -29.6 %.
- Financial health: 28/100 — Strongest input: long-term debt / equity 1.83. Weakest: cash / long-term debt 0.27.
- Momentum: 89/100 — Strongest input: price vs 200-day average +20.0 %. Weakest: 1-year return +37.6 %.
- Attention: 50/100 — Strongest input: headlines in the last 7 days 29. Weakest: volume vs 3-month average 0.3x.
- Risk resilience: 75/100 — Strongest input: annualised volatility (1y) 27.2 %. Weakest: max drawdown (1y) -22.0 %.
- Data confidence: 98/100 — Strongest input: quote age (hours) 0 h. Weakest: inputs available 95 %.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $30.99B | TTM ending 2026-09-30 · 10-Q |
| Revenue growth | 6.5% | TTM ending 2026-09-30 · 10-Q |
| Net income | -$3.86B | TTM ending 2026-09-30 · 10-Q |
| Diluted EPS | -$3.13 | TTM ending 2026-09-30 · 10-Q |
| Operating margin | -7.6% | TTM ending 2026-09-30 · 10-Q |
| Net margin | -12.5% | TTM ending 2026-09-30 · 10-Q |
| Free cash flow | $13.78B | TTM ending 2026-09-30 · 10-Q |
| Cash | $6.44B | as of 2026-09-30 · 10-Q |
| Long-term debt | $23.82B | as of 2026-09-30 · 10-Q |
| Debt / equity | 1.83 | as of 2026-09-30 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0000882095).
Comparable companies for Gilead Sciences
Selected by industry, business overlap and scale; these are not necessarily direct competitors.
- Gilead Sciences vs Amgen (GILD vs AMGN) — Same industry (Drug Manufacturers—General); market cap 1.2x; shares: oncology
- Gilead Sciences vs Pfizer (GILD vs PFE) — Same industry (Drug Manufacturers—General); market cap 0.79x; shares: oncology
- Gilead Sciences vs Bristol-Myers Squibb (GILD vs BMY) — Same industry (Drug Manufacturers—General); market cap 0.60x; shares: oncology
- Gilead Sciences vs Merck & Co. (GILD vs MRK) — Same industry (Drug Manufacturers—General); market cap 1.7x; shares: oncology
- Gilead Sciences vs AbbVie (GILD vs ABBV) — Same industry (Drug Manufacturers—General); market cap 2.5x; shares: oncology
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.